Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Outcomes of pediatric patients transplanted for B-ALL with high-risk cytogenetics- a 20-year experience from LMIC setting

View Full Paper
Ask AI
Bookmark
Share

Authors

RRRawad Rihani

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals a mortality rate of 18% in pediatric patients with high-risk B-ALL after HCT, suggesting a need for improved treatment modalities.

Key Points

  • Eighteen percent of patients died after HCT, with deaths primarily caused by disease relapse.
  • Survival analysis demonstrated critical insights into outcomes for high-risk pediatric patients with B-ALL.
  • Allogeneic hematopoietic cell transplant was performed on pediatric patients showing high-risk cytogenetic features.
  • These findings highlight the necessity for more affordable treatment modalities that can enhance cure rates.],

Cite This Study

Rawad Rihani (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dd0bhttps://doi.org/10.1182/blood-2025-7831
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Allogeneic hematopoietic stem cell transplantation outcomes in pediatric acute lymphoblastic leukemia: A multicenter analysis from the cccg-ALL-2015 protocol2025
  2. 2Allogeneic Hematopoietic Stem Cell Transplantation in Adolescents and Young Adults With Acute Lymphoblastic Leukemia-A Retrospective, Dual-Center Study.2025 · 1 citations
  3. 3Outcome of allogeneic hematopoietic cell transplantation in adult acute lymphoblastic leukemia patients who underwent myeloablative TBI-free conditioning regimen2025 · 1 citations
  4. 4High event-free (EFS) and overall survival (OS) after non-total body irradiation (TBI) conditioning and allogeneic hematopoietic cell transplantation (HCT) in next-generation-sequencing minimal residual disease (NGS-MRD) negative B-acute lymphoblastic leukemia (B-ALL): Results from the EndRAD trial (PTCTC ONC1701)2025 · 2 citations
  5. 5Long-term outcomes of CML patients undergoing hematopoietic stem cell transplantation in the era of tyrosine kinase inhibitors2025